Your browser doesn't support javascript.
loading
Pro-resolving lipid mediators in traumatic brain injury: emerging concepts and translational approach.
Poblete, Roy A; Arenas, Marcela; Sanossian, Nerses; Hong, Young-Kwon; Freeman, William D; Lyden, Patrick D; Louie, Stan G.
Affiliation
  • Poblete RA; Department of Neurology, Keck School of Medicine, The University of Southern California Los Angeles, CA, USA.
  • Arenas M; Department of Neurology, Keck School of Medicine, The University of Southern California Los Angeles, CA, USA.
  • Sanossian N; Department of Neurology, Keck School of Medicine, The University of Southern California Los Angeles, CA, USA.
  • Hong YK; Department of Surgery, Keck School of Medicine, The University of Southern California Los Angeles, CA, USA.
  • Freeman WD; Department of Neurology, College of Medicine and Science, Mayo Clinic Los Angeles, CA, USA.
  • Lyden PD; Department of Neurology, Keck School of Medicine, The University of Southern California Los Angeles, CA, USA.
  • Louie SG; Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, The University of Southern California Los Angeles, CA, USA.
Am J Transl Res ; 14(3): 1482-1494, 2022.
Article in En | MEDLINE | ID: mdl-35422939
ABSTRACT
Despite the high mortality and disability associated with traumatic brain injury (TBI), effective pharmacologic treatments are lacking. Of emerging interest, bioactive lipids, including specialized pro-resolving lipid mediators of inflammation (SPMs), act to attenuate inflammation after injury resolution. The SPM lipidome may serve as a biomarker of disease and predictor of clinical outcomes, and the use of exogenous SPM administration represents a novel therapeutic strategy for TBI. This review article provides a comprehensive discussion of the current pre-clinical and clinical literature supporting the importance of bioactive lipids, including SPMs, in TBI recovery. We additionally propose a translational approach to answer important clinical and scientific questions to advance the study of bioactive lipids and SPMs towards clinical research. Given the morbidity and mortality associated with TBI with limited treatment options, novel approaches are needed.
Key words

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies Language: En Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies Language: En Year: 2022 Type: Article